Ready to reinvent healthcare.
Renovacor, Inc. to Merge with Chardan Healthcare Acquisition 2 Corp.Read More
Renovacor Corporate Presentation
Renovacor, Inc. Announces the Appointment of Matt Killeen, PhD, as Chief Scientific Officer.Read More
A $85 million SPAC seeks to acquire a healthcare company.
Led by an experienced management team, Chardan Healthcare Acquisition 2 Corp. is looking to partner with the next disruptive healthcare company to take public. Chardan leads the effort in using the power of a special purpose acquisition company (SPAC) to bring innovative healthcare ventures to public investors.
Our investment criteria.
Funded Healthcare Company
Venture-backed healthcare company in the biopharma sector
Experienced management team with proven public company success
Actively considering public listing
$250M+ IPO valuation
Post Deal Upside
Upcoming catalysts to drive valuation post business combinations
Contact us for more information about CHAQ.U or Chardan's SPAC practice.
Meet our experienced management team.
Gbola Amusa, MD, CFA
Executive Chairman and Chief Science Officer
President, CEO and Director
CFO, Head of Strategy and Director
Leveraging Chardan post business combination.
Equity Intelligence Platform
A track record of communicating alpha-generative ideas to investors seeking exceptional returns and strong relationships with syndicate partners.
Proprietary access to fundamental buyside investors via NDRs, conferences and KOL events, plus a large geographical investor outreach including both U.S. and Europe.
Meaningful connections with large pharma for near-term M&A idea generation and opportunities.
Academic & Research Institution Relationships
Extensive relationships with leading academic and research institutions to source and support the advancement of groundbreaking healthcare technologies.
We've received your information, and we're processing your request.